FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2119381320> ?p ?o ?g. }

• W2119381320 endingPage "802" @default.
• W2119381320 startingPage "797" @default.
• W2119381320 abstract "The schedule for intravesical chemotherapy administration has not been definitively established in patients with low-grade recurrent non–muscle-invasive bladder cancer (NMIBC). To assess both the feasibility and the efficacy of a short-term intensive schedule of neoadjuvant intravesical chemotherapy in patients with recurrent NMIBC. A randomised phase 2 clinical study included 54 patients with recurrent NMIBC who were submitted to neoadjuvant chemotherapy intravesical instillations according to two different timing schedules. The study was performed at a tertiary care referral centre. Intravesical mitomycin C (MMC) 40 mg/40 ml was administered according to a schedule of either one instillation per week for 6 wk (group 1) or three instillations per week for 2 wk (group 2) prior to transurethral resection (TUR). Local and systemic toxicity were investigated using the US National Cancer Institute's (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v.4.0 questionnaire at each instillation and the SF-36 questionnaire at randomisation and before TUR. A video-recorded cystoscopy and TUR were performed within 14 d after treatment completion. Groups 1 and 2 each were assigned 27 cases. Two patients (7.4%) in group 2 could not complete the scheduled treatment because of severe lower urinary tract symptoms. No statistically significant difference in SF-36 domain score was documented pre- and post-treatment between groups. Likewise, no statistically significant difference in treatment-related toxicity according to the CTCAE v.4 questionnaire was registered. Twelve patients (44.4%) in group 1 and 19 patients (70.4%) in group 2 (p = 0.04) had complete tumour response. The small number of patients included represents the main limitation of the study. The intensive short-term schedule of neoadjuvant chemotherapy is safe and without additional toxicity compared with the weekly regimen. The increased ablative effect may be explained by the improved adherence of the scheduled timing to the duplication rate of tumour cells." @default.
• W2119381320 created "2016-06-24" @default.
• W2119381320 creator A5013076203 @default.
• W2119381320 creator A5031550729 @default.
• W2119381320 creator A5034916881 @default.
• W2119381320 creator A5039363062 @default.
• W2119381320 creator A5051984796 @default.
• W2119381320 creator A5055585541 @default.
• W2119381320 creator A5058674354 @default.
• W2119381320 creator A5059167235 @default.
• W2119381320 creator A5061623935 @default.
• W2119381320 creator A5071652086 @default.
• W2119381320 creator A5078259211 @default.
• W2119381320 creator A5088744931 @default.
• W2119381320 date "2012-11-01" @default.
• W2119381320 modified "2023-10-05" @default.
• W2119381320 title "Neoadjuvant Short-term Intensive Intravesical Mitomycin C Regimen Compared with Weekly Schedule for Low-grade Recurrent Non–muscle-invasive Bladder Cancer: Preliminary Results of a Randomised Phase 2 Study" @default.
• W2119381320 cites W148459091 @default.
• W2119381320 cites W1932210666 @default.
• W2119381320 cites W1968626722 @default.
• W2119381320 cites W1983728421 @default.
• W2119381320 cites W1984756737 @default.
• W2119381320 cites W1995572685 @default.
• W2119381320 cites W1995633792 @default.
• W2119381320 cites W2005064382 @default.
• W2119381320 cites W2010926126 @default.
• W2119381320 cites W2021189681 @default.
• W2119381320 cites W2044110382 @default.
• W2119381320 cites W2064952716 @default.
• W2119381320 cites W2071015810 @default.
• W2119381320 cites W2075118413 @default.
• W2119381320 cites W2095159968 @default.
• W2119381320 cites W2106225846 @default.
• W2119381320 cites W2110599321 @default.
• W2119381320 cites W2140477935 @default.
• W2119381320 cites W2156164249 @default.
• W2119381320 cites W2165798394 @default.
• W2119381320 cites W2338759660 @default.
• W2119381320 cites W40576421 @default.
• W2119381320 doi "https://doi.org/10.1016/j.eururo.2012.05.032" @default.
• W2119381320 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22633362" @default.
• W2119381320 hasPublicationYear "2012" @default.
• W2119381320 type Work @default.
• W2119381320 sameAs 2119381320 @default.
• W2119381320 citedByCount "42" @default.
• W2119381320 countsByYear W21193813202012 @default.
• W2119381320 countsByYear W21193813202013 @default.
• W2119381320 countsByYear W21193813202014 @default.
• W2119381320 countsByYear W21193813202015 @default.
• W2119381320 countsByYear W21193813202016 @default.
• W2119381320 countsByYear W21193813202017 @default.
• W2119381320 countsByYear W21193813202018 @default.
• W2119381320 countsByYear W21193813202019 @default.
• W2119381320 countsByYear W21193813202020 @default.
• W2119381320 countsByYear W21193813202021 @default.
• W2119381320 countsByYear W21193813202022 @default.
• W2119381320 countsByYear W21193813202023 @default.
• W2119381320 crossrefType "journal-article" @default.
• W2119381320 hasAuthorship W2119381320A5013076203 @default.
• W2119381320 hasAuthorship W2119381320A5031550729 @default.
• W2119381320 hasAuthorship W2119381320A5034916881 @default.
• W2119381320 hasAuthorship W2119381320A5039363062 @default.
• W2119381320 hasAuthorship W2119381320A5051984796 @default.
• W2119381320 hasAuthorship W2119381320A5055585541 @default.
• W2119381320 hasAuthorship W2119381320A5058674354 @default.
• W2119381320 hasAuthorship W2119381320A5059167235 @default.
• W2119381320 hasAuthorship W2119381320A5061623935 @default.
• W2119381320 hasAuthorship W2119381320A5071652086 @default.
• W2119381320 hasAuthorship W2119381320A5078259211 @default.
• W2119381320 hasAuthorship W2119381320A5088744931 @default.
• W2119381320 hasConcept C121608353 @default.
• W2119381320 hasConcept C126322002 @default.
• W2119381320 hasConcept C126894567 @default.
• W2119381320 hasConcept C141071460 @default.
• W2119381320 hasConcept C2776694085 @default.
• W2119381320 hasConcept C2777793932 @default.
• W2119381320 hasConcept C2778769751 @default.
• W2119381320 hasConcept C2780352672 @default.
• W2119381320 hasConcept C2781413609 @default.
• W2119381320 hasConcept C71924100 @default.
• W2119381320 hasConcept C77411442 @default.
• W2119381320 hasConceptScore W2119381320C121608353 @default.
• W2119381320 hasConceptScore W2119381320C126322002 @default.
• W2119381320 hasConceptScore W2119381320C126894567 @default.
• W2119381320 hasConceptScore W2119381320C141071460 @default.
• W2119381320 hasConceptScore W2119381320C2776694085 @default.
• W2119381320 hasConceptScore W2119381320C2777793932 @default.
• W2119381320 hasConceptScore W2119381320C2778769751 @default.
• W2119381320 hasConceptScore W2119381320C2780352672 @default.
• W2119381320 hasConceptScore W2119381320C2781413609 @default.
• W2119381320 hasConceptScore W2119381320C71924100 @default.
• W2119381320 hasConceptScore W2119381320C77411442 @default.
• W2119381320 hasIssue "5" @default.
• W2119381320 hasLocation W21193813201 @default.
• W2119381320 hasLocation W21193813202 @default.
• W2119381320 hasOpenAccess W2119381320 @default.
• W2119381320 hasPrimaryLocation W21193813201 @default.
• W2119381320 hasRelatedWork W1874108379 @default.

• next